In this preliminary cross-sectional study including a series of 110 CML patients treated with imatinib or nilotinib, we found that the cluster of co-existing nilotinib treatment, dyslipidaemia and the G allele of LOX-1 polymorphism was the only significant finding associated with atherothrombotic events. The gene discussed is OLR1; the disease is inherited lipid metabolism disorder.